<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796209</url>
  </required_header>
  <id_info>
    <org_study_id>16-00453</org_study_id>
    <nct_id>NCT02796209</nct_id>
  </id_info>
  <brief_title>Norepinephrine Transporter Blockade, Autonomic Failure</brief_title>
  <official_title>Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atomoxetine, a selective norepinephrine transporter (NET) blocker, increases standing blood&#xD;
      pressure and improves neurogenic orthostatic hypotension (NOH)-related symptoms to a greater&#xD;
      extent than midodrine, the current standard of care. Atomoxetine could be a new therapeutic&#xD;
      alternative for the treatment of NOH in patients with autonomic failure, particularly those&#xD;
      with multiple system atrophy (MSA).&#xD;
&#xD;
      The proposed study consists of an open-label, dose-optimization phase followed by a&#xD;
      randomized, double-blind, placebo-controlled, 2x2 crossover phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of Orthostatic Hypotension Questionnaire (OHQ) Score</measure>
    <time_frame>Days 0, 14, 28, 36, 50, and 64</time_frame>
    <description>The OHQ is composed of 10 individual items: 6 items measure specific symptoms (the Orthostatic Hypotension Symptom Assessment [OHSA]), and 4 items measure the impact of those symptoms on a patient's daily activities (the Orthostatic Hypotension Daily Activity Scale [OHDAS])</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple System Atrophy (MSA)</condition>
  <arm_group>
    <arm_group_label>Atomexetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the dose optimization phase, investigators will stratify the treatment assignment by Atomexetine dose (10mg or 19mg twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo capsules will be of identical color, size, and approximate weight to provide an authentic blinded effect. The capsule contents will be a microcrystalline cellulose, NF (PH-105), which should not produce any adverse effects. It is a common pharmaceutical capsule filler used in the industry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomexetine</intervention_name>
    <description>Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).</description>
    <arm_group_label>Atomexetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neurogenic Orthostatic Hypotension (defined by a reduction of â‰¥30 mmHg drop in SBP&#xD;
             within 3 minutes of standing, associated with impaired autonomic reflexes as assessed&#xD;
             by autonomic function tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria,&#xD;
             anaphylaxis)&#xD;
&#xD;
          -  Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion),&#xD;
             Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella&#xD;
             (milnacipran)&#xD;
&#xD;
          -  Previous history (within 14 days prior to enrollment) and current use of monoamine&#xD;
             oxidase inhibitors&#xD;
&#xD;
          -  Concomitant use of strong CYP2D6 inhibitors such as delavirdine, paroxetine,&#xD;
             fluoxetine, quinidine&#xD;
&#xD;
          -  Pre-existing sustained severe hypertension (BP 140/80 mmhg in the sitting position)&#xD;
&#xD;
          -  Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino&#xD;
             transaminase [ALT] &gt;2 x upper limit of normal range)&#xD;
&#xD;
          -  Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment&#xD;
&#xD;
          -  Congestive heart failure (LV hypertrophy acceptable)&#xD;
&#xD;
          -  History of serious neurologic disease such as cerebral hemorrhage, or stroke&#xD;
&#xD;
          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, unlikelihood of completing the study, and mental&#xD;
             conditions rendering the subject unable to understand the nature, scope, and possible&#xD;
             consequences of the study&#xD;
&#xD;
          -  Patients with narrow angle glaucoma&#xD;
&#xD;
          -  Patients with or a history of pheochromocytoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horacio Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atomoxetine</keyword>
  <keyword>autonomic failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

